NYSE:CRL - Charles River Laboratories Stock Price, Price Target & More

$106.52 +1.06 (+1.01 %)
(As of 04/24/2018 06:18 AM ET)
Previous Close$105.46
Today's Range$105.81 - $107.56
52-Week Range$86.66 - $119.05
Volume124,600 shs
Average Volume396,152 shs
Market Capitalization$5.00 billion
P/E Ratio19.97
Dividend YieldN/A
Beta0.68

About Charles River Laboratories (NYSE:CRL)

Charles River Laboratories logoCharles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000

Debt

Debt-to-Equity Ratio1.06%
Current Ratio1.78%
Quick Ratio1.54%

Price-To-Earnings

Trailing P/E Ratio19.97
Forward P/E Ratio18.46
P/E Growth1.58

Sales & Book Value

Annual Sales$1.86 billion
Price / Sales2.72
Cash Flow$8.2574 per share
Price / Cash12.90
Book Value$22.11 per share
Price / Book4.82

Profitability

EPS (Most Recent Fiscal Year)$5.27
Net Income$123.35 million
Net Margins6.64%
Return on Equity26.14%
Return on Assets9.09%

Miscellaneous

Employees11,800
Outstanding Shares47,430,000

How to Become a New Pot Stock Millionaire

Charles River Laboratories (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories' stock symbol?

Charles River Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories' stock buyback program work?

Charles River Laboratories announced that its board has authorized a stock buyback program on Sunday, June 4th 2017, which permits the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's management believes its stock is undervalued.

How were Charles River Laboratories' earnings last quarter?

Charles River Laboratories (NYSE:CRL) issued its earnings results on Tuesday, February, 13th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. The medical research company had revenue of $478.50 million for the quarter, compared to analysts' expectations of $475.02 million. Charles River Laboratories had a net margin of 6.64% and a return on equity of 26.14%. The company's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.21 earnings per share. View Charles River Laboratories' Earnings History.

When is Charles River Laboratories' next earnings date?

Charles River Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Charles River Laboratories.

What price target have analysts set for CRL?

13 equities research analysts have issued 12 month price objectives for Charles River Laboratories' stock. Their forecasts range from $102.00 to $130.00. On average, they expect Charles River Laboratories' stock price to reach $115.7692 in the next year. View Analyst Ratings for Charles River Laboratories.

Who are some of Charles River Laboratories' key competitors?

Who are Charles River Laboratories' key executives?

Charles River Laboratories' management team includes the folowing people:
  • Mr. James C. Foster, Chairman & CEO (Age 67)
  • Dr. Davide A. Molho, Pres & COO (Age 48)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 52)
  • Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 57)

Has Charles River Laboratories been receiving favorable news coverage?

Press coverage about CRL stock has trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Charles River Laboratories earned a media sentiment score of 0.24 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 46.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Charles River Laboratories?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories' stock price today?

One share of CRL stock can currently be purchased for approximately $106.52.

How big of a company is Charles River Laboratories?

Charles River Laboratories has a market capitalization of $5.00 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories employs 11,800 workers across the globe.

How can I contact Charles River Laboratories?

Charles River Laboratories' mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories (CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  333 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Charles River Laboratories (NYSE:CRL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Charles River Laboratories in the last 12 months. Their average twelve-month price target is $115.7692, suggesting that the stock has a possible upside of 8.68%. The high price target for CRL is $130.00 and the low price target for CRL is $102.00. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyHoldHold
Consensus Rating Score: 2.462.502.402.44
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $115.7692$115.8333$111.0909$101.25
Price Target Upside: 8.68% upside2.73% upside2.97% upside10.33% downside

Charles River Laboratories (NYSE:CRL) Consensus Price Target History

Price Target History for Charles River Laboratories (NYSE:CRL)

Charles River Laboratories (NYSE:CRL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$115.00LowView Rating Details
3/14/2018Morgan StanleyReiterated RatingEqual Weight -> Equal Weight$94.00 -> $102.00LowView Rating Details
2/16/2018BarclaysReiterated RatingHold$110.00LowView Rating Details
2/15/2018Credit Suisse GroupReiterated RatingHold$108.00LowView Rating Details
2/14/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$110.00 -> $120.00MediumView Rating Details
2/14/2018SunTrust BanksUpgradeHold -> Buy$107.66 -> $125.00MediumView Rating Details
2/13/2018Royal Bank of CanadaSet Price TargetHold$116.00HighView Rating Details
2/13/2018Robert W. BairdSet Price TargetBuy$123.00HighView Rating Details
1/18/2018Evercore ISIInitiated CoverageIn -> In-Line$117.00LowView Rating Details
12/13/2017ArgusInitiated CoverageBuy -> Buy$120.00MediumView Rating Details
11/10/2017Bank of AmericaLower Price TargetBuy$117.00 -> $115.00N/AView Rating Details
10/9/2017Jefferies GroupBoost Price TargetBuy$120.00 -> $130.00N/AView Rating Details
6/28/2017CitigroupReiterated RatingNeutral$91.00 -> $104.00LowView Rating Details
2/15/2017UBSBoost Price Target$84.00N/AView Rating Details
12/16/2016Goldman SachsUpgradeSell -> Neutral$75.00 -> $77.00N/AView Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00N/AView Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Charles River Laboratories (NYSE:CRL) Earnings History and Estimates Chart

Earnings by Quarter for Charles River Laboratories (NYSE:CRL)

Charles River Laboratories (NYSE:CRL) Earnings Estimates

2018 EPS Consensus Estimate: $5.59
2019 EPS Consensus Estimate: $6.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.24$1.30$1.26
Q2 20185$1.40$1.52$1.44
Q3 20185$1.38$1.44$1.40
Q4 20184$1.44$1.55$1.49
Q1 20191$1.56$1.56$1.56
Q2 20191$1.67$1.67$1.67
Q3 20191$1.62$1.62$1.62
Q4 20191$1.68$1.68$1.68

Charles River Laboratories (NYSE CRL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$1.27N/AView Earnings Details
2/13/2018Q4 2017$1.26$1.40$475.02 million$478.50 millionViewListenView Earnings Details
11/9/2017Q3 2017$1.22$1.30$458.93 million$464.23 millionViewN/AView Earnings Details
8/9/2017Q2 2017$1.22$1.29$458.25 million$469.13 millionViewListenView Earnings Details
5/10/2017Q1 2017$1.1420$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
11/3/2010Q3 2010$0.49$0.45ViewN/AView Earnings Details
8/2/2010Q2 2010$0.50$0.49ViewN/AView Earnings Details
4/26/2010Q1 2010$0.47$0.45ViewN/AView Earnings Details
2/8/2010Q4 2009$0.43$0.49ViewN/AView Earnings Details
11/3/2009Q3 2009$0.60$0.65ViewN/AView Earnings Details
8/4/2009Q2 2009$0.58$0.66ViewN/AView Earnings Details
5/5/2009Q1 2009$0.53$0.58ViewN/AView Earnings Details
2/9/2009Q4 2008$0.55$0.59ViewN/AView Earnings Details
11/5/2008Q3 2008$0.74$0.76ViewN/AView Earnings Details
8/5/2008Q2 2008$0.73$0.79ViewN/AView Earnings Details
5/6/2008Q1 2008$0.68$0.72ViewN/AView Earnings Details
2/11/2008Q4 2007$0.64$0.65ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Charles River Laboratories (NYSE:CRL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Charles River Laboratories (NYSE CRL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 99.97%
Insider Trading History for Charles River Laboratories (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories (NYSE:CRL)

Charles River Laboratories (NYSE CRL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018George M Milne JrDirectorSell7,740$115.00$890,100.0036,760View SEC Filing  
3/6/2018Birgit GirshickInsiderSell9,893$109.10$1,079,326.3026,470View SEC Filing  
3/6/2018James C FosterCEOSell24,008$110.00$2,640,880.00325,684View SEC Filing  
2/28/2018David Ross SmithCFOSell100$108.43$10,843.0013,103View SEC Filing  
2/28/2018James C FosterCEOSell3,372$107.39$362,119.08324,012View SEC Filing  
2/26/2018David Ross SmithInsiderSell3,868$107.35$415,229.8018,483View SEC Filing  
2/26/2018James C FosterCEOSell4,800$106.69$512,112.00306,914View SEC Filing  
2/21/2018William D BarboInsiderSell2,320$108.08$250,745.6021,276View SEC Filing  
2/16/2018David Ross SmithInsiderSell3,639$109.07$396,905.7315,110View SEC Filing  
2/15/2018James C FosterChairmanSell46$107.50$4,945.00292,621View SEC Filing  
2/15/2018Stephen D ChubbDirectorSell2,872$108.70$312,186.4036,461View SEC Filing  
1/18/2018Online Communications BdirectDirectorSell131,000$0.29$37,990.00
1/2/2018David Ross SmithInsiderSell5,486$109.53$600,881.58View SEC Filing  
1/2/2018James C FosterChairmanSell4,967$109.44$543,588.48329,928View SEC Filing  
1/2/2018Robert J BertoliniDirectorSell3,609$110.22$397,783.98View SEC Filing  
12/12/2017Kevin MaDirectorSell40,384$0.41$16,557.44
12/6/2017C Richard ReeseDirectorSell10,227$102.40$1,047,244.8051,444View SEC Filing  
11/10/2017Bradley Nixon ScharfeInsiderSell1,000,000$0.27$270,000.00
10/30/2017Bradley Nixon ScharfeInsiderBuy2,500$0.25$625.00
10/25/2017Bradley Nixon ScharfeInsiderBuy3,000$0.27$810.00
10/19/2017Bradley Nixon ScharfeInsiderBuy2,000$0.29$580.00
10/17/2017Bradley Nixon ScharfeInsiderBuy3,000$0.29$870.00
10/5/2017Davide MolhoInsiderSell6,165$110.00$678,150.00View SEC Filing  
9/5/2017Davide MolhoInsiderSell5,982$107.55$643,364.1022,714View SEC Filing  
8/17/2017William D BarboInsiderSell4,000$99.91$399,640.0020,424View SEC Filing  
8/14/2017David Ross SmithInsiderSell2,552$67.10$171,239.2011,671View SEC Filing  
7/17/2017George MassaroDirectorSell3,830$100.81$386,102.3018,731View SEC Filing  
7/10/2017James C FosterChairmanSell9,516$98.92$941,322.72361,171View SEC Filing  
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.0027,497View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00361,178View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.0014,203View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.8427,525View SEC Filing  
5/23/2017Jason Wesley ScharfeDirectorSell10,000$0.31$3,100.00
5/17/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.0015,831View SEC Filing  
5/11/2017Jason Wesley ScharfeDirectorSell6,000$0.36$2,160.00
5/10/2017Jason Wesley ScharfeDirectorSell9,000$0.36$3,240.00
3/29/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.0028,266View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58201,005View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.0022,224View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.8017,085View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.1532,140View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90381,730View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88388,294View SEC Filing  
2/22/2017Jason Wesley ScharfeDirectorBuy15,000$0.29$4,350.00
2/21/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/17/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/15/2017Jason Wesley ScharfeDirectorBuy4,500$0.30$1,350.00
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00174,696View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.4830,849View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.2744,943View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13383,283View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.0024,190View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.6018,935View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.006,883View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.4017,690View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.0027,420View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.4513,020View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.0015,430View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.0079,008View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.0023,809View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.0021,953View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50189,023View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20402,707View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.8038,200View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72402,964View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.4431,123View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.0025,392View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.0011,504View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.0013,120View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00100,635View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00100,635View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12100,635View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.0013,504View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.0011,370View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.0016,510View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80113,781View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.6038,515View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.0048,625View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.0023,645View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.2655,722View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.0043,162View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.1250,235View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.0050,510View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.3025,645View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00105,539View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00141,799View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.0015,410View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00107,689View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.0054,192View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.0026,843View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.0415,410View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.0028,843View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00366,580View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.0040,892View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.0030,843View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.5055,085View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.0016,700View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.0040,892View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.9413,870View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50105,039View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Charles River Laboratories (NYSE CRL) News Headlines

Source:
DateHeadline
Charles River Laboratories (CRL) Research Coverage Started at Mitsubishi UFJ Financial GroupCharles River Laboratories (CRL) Research Coverage Started at Mitsubishi UFJ Financial Group
www.americanbankingnews.com - April 20 at 10:25 AM
Charles River Laboratories International Breaks Below 200-Day Moving Average - Notable for CRLCharles River Laboratories International Breaks Below 200-Day Moving Average - Notable for CRL
www.nasdaq.com - April 20 at 9:09 AM
National Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head ContrastNational Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head Contrast
www.americanbankingnews.com - April 19 at 3:26 AM
Charles River Laboratories (CRL) Rating Reiterated by BarclaysCharles River Laboratories (CRL) Rating Reiterated by Barclays
www.americanbankingnews.com - April 17 at 4:47 PM
$481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter$481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter
www.americanbankingnews.com - April 16 at 2:13 AM
Charles River Laboratories (CRL) Rating Lowered to Buy at BidaskClubCharles River Laboratories (CRL) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 11:27 PM
Zacks: Brokerages Anticipate Charles River Laboratories (CRL) Will Post Earnings of $1.26 Per ShareZacks: Brokerages Anticipate Charles River Laboratories (CRL) Will Post Earnings of $1.26 Per Share
www.americanbankingnews.com - April 14 at 9:10 PM
Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference CallCharles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference Call
finance.yahoo.com - April 12 at 4:54 PM
Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018
finance.yahoo.com - April 10 at 9:23 AM
Charles River to invest in next-gen sequencing outfit PathoQuestCharles River to invest in next-gen sequencing outfit PathoQuest
seekingalpha.com - April 9 at 9:12 AM
Contrasting Luna Innovations (LUNA) and Charles River Laboratories (CRL)Contrasting Luna Innovations (LUNA) and Charles River Laboratories (CRL)
www.americanbankingnews.com - April 9 at 3:13 AM
Charles River Laboratories (CRL) Rating Reiterated by Jefferies GroupCharles River Laboratories (CRL) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 8 at 11:23 PM
Charles River Laboratories (CRL) Stock Rating Lowered by ValuEngineCharles River Laboratories (CRL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 7 at 10:27 AM
Charles River Laboratories (CRL) Receives Average Recommendation of "Buy" from AnalystsCharles River Laboratories (CRL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 10:44 AM
Charles River Laboratories Announces Closing of Senior Notes OfferingCharles River Laboratories Announces Closing of Senior Notes Offering
finance.yahoo.com - April 3 at 9:14 AM
Charles River Laboratories Completes the Acquisition of MPI ResearchCharles River Laboratories Completes the Acquisition of MPI Research
finance.yahoo.com - April 3 at 9:14 AM
$480.70 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter$480.70 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter
www.americanbankingnews.com - March 31 at 4:52 AM
$1.25 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter$1.25 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter
www.americanbankingnews.com - March 29 at 1:18 AM
SunTrust Banks Downgrades Charles River Laboratories Intl. (CRL) to HoldSunTrust Banks Downgrades Charles River Laboratories Intl. (CRL) to Hold
www.americanbankingnews.com - March 27 at 10:27 AM
Charles River Laboratories Intl, Inc. -- Moodys assigns B1 to Charles Rivers unsecured notes; secured term loan upgraded to Ba1Charles River Laboratories Int'l, Inc. -- Moody's assigns B1 to Charles River's unsecured notes; secured term loan upgraded to Ba1
finance.yahoo.com - March 26 at 4:42 PM
Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior NotesCharles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior Notes
finance.yahoo.com - March 26 at 9:22 AM
Charles River Laboratories Intl. (CRL) Given New $102.00 Price Target at Morgan StanleyCharles River Laboratories Intl. (CRL) Given New $102.00 Price Target at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:44 AM
Charles River Laboratories Intl. Inc (CRL) Director George M. Milne, Jr. Sells 7,740 SharesCharles River Laboratories Intl. Inc (CRL) Director George M. Milne, Jr. Sells 7,740 Shares
www.americanbankingnews.com - March 13 at 1:25 PM
Charles River Laboratories Intl. Inc (CRL) Expected to Announce Quarterly Sales of $480.70 MillionCharles River Laboratories Intl. Inc (CRL) Expected to Announce Quarterly Sales of $480.70 Million
www.americanbankingnews.com - March 13 at 5:46 AM
Zacks: Analysts Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Earnings of $1.25 Per ShareZacks: Analysts Anticipate Charles River Laboratories Intl. Inc (CRL) Will Announce Earnings of $1.25 Per Share
www.americanbankingnews.com - March 11 at 4:25 PM
Charles River Laboratories Intl. Inc (CRL) Given Average Recommendation of "Buy" by BrokeragesCharles River Laboratories Intl. Inc (CRL) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 9:44 AM
Charles River Laboratories Makes Expansions to Global Biologics InfrastructureCharles River Laboratories Makes Expansions to Global Biologics Infrastructure
finance.yahoo.com - March 8 at 9:15 AM
Charles River Laboratories Intl. Inc (CRL) Insider Sells $1,079,326.30 in StockCharles River Laboratories Intl. Inc (CRL) Insider Sells $1,079,326.30 in Stock
www.americanbankingnews.com - March 7 at 6:35 PM
James C. Foster Sells 24,008 Shares of Charles River Laboratories Intl. Inc (CRL) StockJames C. Foster Sells 24,008 Shares of Charles River Laboratories Intl. Inc (CRL) Stock
www.americanbankingnews.com - March 7 at 6:17 PM
Charles River Laboratories (CRL) Presents At Raymond James 39th Annual Institutional Investors Conference -SlideshowCharles River Laboratories (CRL) Presents At Raymond James 39th Annual Institutional Investors Conference -Slideshow
seekingalpha.com - March 7 at 5:42 PM
Charles River Laboratories Intl. Inc (CRL) Position Increased by Kennedy Capital Management Inc.Charles River Laboratories Intl. Inc (CRL) Position Increased by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 6 at 1:09 PM
Charles River Laboratories Intl. Inc (CRL) Stake Lowered by WINTON GROUP LtdCharles River Laboratories Intl. Inc (CRL) Stake Lowered by WINTON GROUP Ltd
www.americanbankingnews.com - March 5 at 4:08 PM
Charles River Laboratories Intl. Inc (CRL) Shares Bought by The Manufacturers Life Insurance Company Charles River Laboratories Intl. Inc (CRL) Shares Bought by The Manufacturers Life Insurance Company
www.americanbankingnews.com - March 5 at 1:56 PM
Charles River Laboratories to Present at Raymond James and Barclays ConferencesCharles River Laboratories to Present at Raymond James and Barclays Conferences
finance.yahoo.com - March 5 at 9:06 AM
BlackRock Inc. Increases Position in Charles River Laboratories Intl. Inc (CRL)BlackRock Inc. Increases Position in Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - March 4 at 4:52 AM
Commerce Bank Purchases 8,966 Shares of Charles River Laboratories Intl. Inc (CRL)Commerce Bank Purchases 8,966 Shares of Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - March 3 at 5:28 AM
Charles River Laboratories Intl. Inc (CRL) Shares Sold by Bank of New York Mellon CorpCharles River Laboratories Intl. Inc (CRL) Shares Sold by Bank of New York Mellon Corp
www.americanbankingnews.com - March 3 at 4:42 AM
Snyder Capital Management L P Has $7.36 Million Stake in Charles River Laboratories Intl. Inc (CRL)Snyder Capital Management L P Has $7.36 Million Stake in Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - March 2 at 1:57 PM
Insider Selling: Charles River Laboratories Intl. Inc (CRL) CFO Sells 100 Shares of StockInsider Selling: Charles River Laboratories Intl. Inc (CRL) CFO Sells 100 Shares of Stock
www.americanbankingnews.com - March 2 at 12:53 PM
Charles River Laboratories Intl. Inc (CRL) Shares Bought by Schroder Investment Management GroupCharles River Laboratories Intl. Inc (CRL) Shares Bought by Schroder Investment Management Group
www.americanbankingnews.com - March 2 at 9:58 AM
Insider Selling: Charles River Laboratories Intl. Inc (CRL) CEO Sells 3,372 Shares of StockInsider Selling: Charles River Laboratories Intl. Inc (CRL) CEO Sells 3,372 Shares of Stock
www.americanbankingnews.com - March 2 at 9:30 AM
Charles River Laboratories Intl. Inc (CRL) Position Increased by Channing Capital Management LLCCharles River Laboratories Intl. Inc (CRL) Position Increased by Channing Capital Management LLC
www.americanbankingnews.com - March 2 at 5:32 AM
California Public Employees Retirement System Raises Stake in Charles River Laboratories Intl. Inc (CRL)California Public Employees Retirement System Raises Stake in Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - March 2 at 5:21 AM
Charles River Laboratories Intl. Inc (CRL) Position Increased by Arizona State Retirement SystemCharles River Laboratories Intl. Inc (CRL) Position Increased by Arizona State Retirement System
www.americanbankingnews.com - March 2 at 4:30 AM
With A -20.00% Earnings Drop Lately, Did Charles River Laboratories International Inc (NYSE:CRL) Underperform Its Industry?With A -20.00% Earnings Drop Lately, Did Charles River Laboratories International Inc (NYSE:CRL) Underperform Its Industry?
finance.yahoo.com - March 1 at 5:13 PM
Charles River Laboratories Intl. Inc (CRL) Stake Lowered by Globeflex Capital L PCharles River Laboratories Intl. Inc (CRL) Stake Lowered by Globeflex Capital L P
www.americanbankingnews.com - March 1 at 5:04 PM
Charles River Laboratories Intl. Inc (CRL) Stake Increased by Mackenzie Financial CorpCharles River Laboratories Intl. Inc (CRL) Stake Increased by Mackenzie Financial Corp
www.americanbankingnews.com - March 1 at 12:41 PM
Charles River Laboratories Intl. Inc (CRL) Stake Lowered by Liberty Mutual Group Asset Management Inc.Charles River Laboratories Intl. Inc (CRL) Stake Lowered by Liberty Mutual Group Asset Management Inc.
www.americanbankingnews.com - March 1 at 11:14 AM
Charles River Laboratories Intl. Inc (CRL) CEO James C. Foster Sells 4,800 SharesCharles River Laboratories Intl. Inc (CRL) CEO James C. Foster Sells 4,800 Shares
www.americanbankingnews.com - February 28 at 6:34 PM
King Luther Capital Management Corp Decreases Position in Charles River Laboratories Intl. Inc (CRL)King Luther Capital Management Corp Decreases Position in Charles River Laboratories Intl. Inc (CRL)
www.americanbankingnews.com - February 28 at 1:19 PM

SEC Filings

Charles River Laboratories (NYSE:CRL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Charles River Laboratories (NYSE:CRL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Charles River Laboratories (NYSE CRL) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.